Canopy Growth

Q4 FY2026 EarningsFY26 net revenue reached $284.6M, up 6% YoY, driven by 20% growth in Canadian adult-use and 18% in medical cannabis. Gross margin contracted to 24% from 30% due to higher inventory provisions and new product launch costs. Net loss from continuing operations narrowed by 49% to $262.9M, primarily due to lower non-cash fair value losses on Canopy USA assets and reduced interest expense. Diluted EPS was $(0.88) compared to $(4.79) in FY25.